Immunocore Holdings Reaffirms Buy Rating with $60 Price Target

Immunocore Holdings has received a Buy rating from Leerink Partners, with a price target of $60. Analyst Jonathan Chang maintained the rating in a report yesterday. Chang has an average return of -11.2% and a 30.61% success rate. Immunocore Holdings' market cap is $1.61B and P/E ratio is -77.10.

Immunocore Holdings PLC (IMCR) has reported its second quarter (Q2) 2025 financial results, with the company posting a quarterly adjusted loss of 20 cents per share. This figure was higher than the same quarter last year when the company reported EPS of -23 cents. The mean expectation of fifteen analysts for the quarter was for a loss of 21 cents per share, while Wall Street expected results to range from -51 cents to -5 cents per share [1].

Revenue for the quarter ended June 30, 2025, rose by 30% to $97.96 million compared to the same period last year, surpassing the expected $94.77 million. This increase in revenue was driven by the company's strong pipeline progress and strategic initiatives.

Analyst Jonathan Chang of Leerink Partners maintained a Buy rating on Immunocore Holdings, with a price target of $60. Chang's average return is -11.2%, and his success rate is 30.61%. The company's market capitalization stands at $1.61 billion, with a P/E ratio of -77.10 [1].

Immunocore Holdings has been actively engaged in various clinical trials and strategic partnerships, aiming to advance its pipeline of cancer therapies. The company's recent achievements, such as the initiation of dosing in a rare eye disease Phase III study and the successful enrollment of the first patient in its Phase 3 ATOM trial, have contributed to its strong market position [2].

The company's ongoing efforts to expand its clinical trials and strategic collaborations are expected to drive future growth and potentially improve its financial performance. Investors and financial professionals should closely monitor Immunocore Holdings' progress and future earnings reports to gauge its potential for growth and value creation.

References:
[1] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TZ2NC:0-immunocore-holdings-plc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[2] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TZ2NC:0-immunocore-holdings-plc-reports-results-for-the-quarter-ended-june-30-earnings-summary/